

U.S. Application No. 10/524,300
Filing Date August 29, 2005
First Inventor Jingwu Z. Zhang
Art Unit 1644
Examiner DIBRINO, MARIANNE NMN
Docket Number 050989.0201.01USPC

Information Disclosure Statement

Examiner Initials	Cite No#	Authors, Title, Journal, Date, Year, Pages, Volume
	C1	CORREALE, J, et al. Isolation and characterization of autoreactive proteolipid protein specific T-cell clones from multiple sclerosis patients. <i>Neurology</i> 1995 45:1370-8
	C2	WARREN, KG et al. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. <i>Ann Neurol</i> 1994 35:280-9
	C3	OLSSON, T et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. <i>J Clin Invest</i> 1990 86:981-5
M.D./	C99	JESSEE, D., "Notice of Grant Award," for National Institutes of Health Grant No. 1 R01 NS38213-01A1. Awarded to Dr. Leslie P. Weiner on 07/30/1999. Obtained pursuant to Freedom of Information Act.
	C99A	WEINER, L., Grant Application entitled, "T Cell Vaccine--A Clinical Trial for Progressive MS." National Institutes of Health Grant No. 1 R01 NS38213-01A1. Awarded on 07/30/1999. Obtained pursuant to Freedom of Information Act.
	C100	JESSEE, D., "Notice of Grant Award," for National Institutes of Health Grant No. 5 R01 NS38213-02. Awarded to Dr. Leslie P. Weiner on 07/24/2000. Obtained pursuant to Freedom of Information Act.
	C100A	WEINER, L., Grant Application entitled, "T Cell Vaccine--A Clinical Trial for Progressive MS." National Institutes of Health Grant No. 5 R01 NS38213-02. Awarded on 07/24/2000. Obtained pursuant to Freedom of Information Act.
	C101	JESSEE, D., "Notice of Grant Award," for National Institutes of Health Grant No. 5 R01 NS38213-03. Awarded to Dr. Leslie P. Weiner on 08/05/2001. Obtained pursuant to Freedom of Information Act.
	C101A	WEINER, L., Grant Application entitled, "T Cell Vaccine--A Clinical Trial for Progressive MS." National Institutes of Health Grant No. 5 R01 NS38213-03. Awarded on 08/05/2001. Obtained pursuant to Freedom of Information Act.
	C102	BOND, K.P., "Notice of Grant Award," for National Institutes of Health Grant No. 5 R01 NS38213-04. Awarded to Dr. Leslie P. Weiner on 08/08/2002. Obtained pursuant to Freedom of Information Act.
	C102A	WEINER, L., Grant application entitled, "T Cell Vaccine--A Clinical Trial for Progressive MS." National Institutes of Health Grant No. 5 R01 NS38213-04. Awarded on 08/08/2002. Obtained pursuant to Freedom of Information Act.
	C103	BOND, K.P., "Notice of Grant Award," for National Institutes of Health Grant No. 5 R01 NS38213-05. Awarded to Dr. Leslie P. Weiner on 09/17/2003. Obtained pursuant to Freedom of Information Act.
	C103A	WEINER, L., Grant application entitled, "T Cell Vaccine--A Clinical Trial for Progressive MS." National Institutes of Health Grant No. 5 R01 NS38213-05. Awarded on 09/17/2003. Obtained pursuant to Freedom of Information Act.
	C104	BOND, K.P., "Notice of Grant Award," for National Institutes of Health Grant No. 5 R01 NS38213-06. Awarded to Dr. Leslie P. Weiner on 07/23/2004. Obtained pursuant to Freedom of Information Act.
	C104A	WEINER, L., Grant application entitled, "T Cell Vaccine--A Clinical Trial for Progressive MS." National Institutes of Health Grant No. 5 R01 NS38213-06. Awarded on 07/23/2004. Obtained pursuant to Freedom of Information Act.
	C105	BOND, K.P., "Notice of Grant Award," for National Institutes of Health Grant No. 5 R01 NS38213-07. Awarded to Dr. Leslie P. Weiner on 08/03/2005. Obtained pursuant to Freedom of Information Act.
	C105A	WEINER, L., Grant application entitled, "T Cell Vaccine--A Clinical Trial for Progressive MS." National Institutes of Health Grant No. 5 R01 NS38213-07. Awarded on 08/03/2005. Obtained pursuant to Freedom of Information Act.
	C38	ZANG, CQ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells introduced by T cell vaccination. <i>Journal of Immunology</i> 164:4011-7 (2000)
	C73	HOFFIELD, R. The ups and downs of multiple sclerosis therapeutics. <i>Annals of Neurology</i> 49(3): 281-84 (2001)
M.D./	C74	JOSHI, N. The T-cell response to myelin basic protein in familial multiple sclerosis: diversity of fine specificity, restricting elements, and T-cell receptor usage. <i>Annals of Neurology</i> 34:385-93 (1993)

Examiner Initials	Cite No#	NON PATENT LITERATURE DOCUMENTS Authors, Title, Journal, Date, Year, Pages, Volume
/M.D./	C75	TOURNIER-LASSERVE, E. Human T-cell response to myelin basic protein in multiple sclerosis patients and healthy subjects. Journal of Neuroscience Research 19:149-56 (1988)
	C76	PETTE, M. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40:1770-6 (1990)
	C77	LIBLAU, R. T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects. Eur J Immunol 21:1391-5 (1991)
	C78	SHANMUGAM, A. In vivo clonal expansion of T lymphocytes specific for an immunodominant N-terminal myelin basic protein epitope in healthy individuals. Journal of Neuroimmunology 59:165-72 (1995)
	C79	HELLINGS, N. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. Journal of Neuroscience Research 63: 290-302 (2001)
	C80	MARTIN, R. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. Journal of Immunology 148:1359-66 (1992)
	C81	PETTE, M. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DRA2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA 87:7968-72 (1990)
	C82	BLEVINS, G. Future immunotherapies in multiple sclerosis. Semin Neurol 23(2):147-58 (2003)
	C83	FELDMAN, M. Design of effective immunotherapy for human autoimmunity. Nature 435:612-9 (2005)
	C84	HONG, J. Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. Eur J Immunol 34:870-81 (2004)
	C85	MARTIN, R. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. Journal of Immunology 145:540-8 (1990)
	C86	HELLINGS, N. Longitudinal study of antimyelin T cell reactivity in relapsing remitting multiple sclerosis association with clinical and MRI activity. J Neuroimmunol 126(1-2):143-60 (2002)
	C87	SOSPREDÀ, M. Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747 (2005)
	C88	MARTIN, R. Immunotherapy of multiple sclerosis: where are we? where should we go?. Nature Immunology 2(9):785-8 (2001)
	C89	MURARRO, P.A. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126:20-31 (2003)
	C90	PENDER, M.P. A study of human T cell lines generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein. Journal of Neuroimmunology 70(1):65-74 (1996)
	C91	LUTTON, J.D. Multiple sclerosis: etiological mechanisms and future directions. Exp Biol Med 229:12-20 (2004)
	C92	DORNMAIR, K. T-cell mediated autoimmunity. Am J Pathol 163(4):1215-26 (2003)
	C93	SODERSTORM, M. T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. Scand J Immunol 37:355-68 (1993)
	C94	KAPPOS, L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Medicine 6(9): 1176-82 (2002)
	C95	WIENDL, H. Therapeutic approaches in multiple sclerosis. Biodrugs 16(3): 183-200 (2002)
	C96	BIELEKOVA, B. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Medicine 6(10): 1167-75 (2000)
	C97	WUCHERPFENNIG, K.W. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. J Clin Invest 100(5): 1114-22 (1997)
/M.D./	C98	MEINL, E. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. J Clin Invest 92: 2633-43 (1993)
	C36	ZHANG, J et al. T-cell vaccination in autoimmune diseases. Human Immunology 38:87-96 (1993)
	C57	ACHIRON, A. T-cell vaccination in multiple sclerosis. Autoimmunity Reviews 3 25-32 (2004)
	C58	ACHIRON, A. et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clinical Immunology 110:155-60 (2004)
	C59	BEN-NUN, A. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced diseases. Journal Neurol 243(1) S14-S22 (1996)
	C50	BEN-NUN, A. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur Journal Immunol 11:195-99 (1981)

Examiner Initials	Cite No#	Authors, Title, Journal, Date, Year, Pages, Volume
		NON PATENT LITERATURE DOCUMENTS
	C61	BEN-NUN, A. Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein. <i>Nature</i> 292(5919):60-61 (1981)
	C62	HELLINGS, N. et al. T cell vaccination in multiple sclerosis: update on clinical application and mode of action. <i>Autoimmunity Reviews</i> 3:267-75 (2004)
/M.D./	C63	HERMANS, G. et al. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. <i>Journal of Autoimmunity</i> 13:233-46 (1999)
	C64	HERMANS, G. et al. Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. <i>Journal of Neuroimmunology</i> 102:79-84 (2000)
	C65	STINISSEN, P. et al. gamma-delta T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination. <i>Journal of Neuroimmunology</i> 87:94-104 (1998)
	C66	WARREN, K.G. et al. Purification of primary antibodies of the myelin basic protein antibody cascade from multiple sclerosis patients: immunoreactivity studies with homologous and heterologous antigens. <i>Clin Invest Med</i> 15(1): 18-29 (1992)
	C67	ZHANG, J. Multiple sclerosis: perspectives on autoimmune pathology and prospects for therapy. <i>Current Neurology</i> 15:115-55 (1995)
	C68	ZHANG, J. et al. In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. <i>Journal of Immunology</i> 155:5868-77 (1995)
/M.D./	C69	ZHANG, J. et al. Myelin basic protein-reactive T cells in multiple sclerosis: pathologic relevance and therapeutic targeting. <i>Cytotechnology</i> 16:181-87 (1994)
	C70	ZHANG, J. et al. T cell vaccination in multiple sclerosis: hopes and facts. 94:112-15 (1994)
	C71	ZIPP, F., et al. Aktuelle Therapie der Multiplen Sklerose: T-Zellvakzination. <i>Neuroarzt</i> , Vol. 65, pp. 424-425 (1998)
/M.D./	C72	ZIPP, F. et al. Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. <i>Brain</i> 121:1395-1407 (1998)
	C12	JOHNSON et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. <i>Neurol</i> 45:1268-76 (1995)
	C19	NAPARSTEK et al. T lymphocyte lines producing or vaccinating against autoimmune encephalomyelitis (EAE): functional activation induces peanut agglutinin receptors and accumulation in the brain and thymus of line cells. <i>Eur J Immunol</i> 13:418-23
	C49	ZHANG, J., et al. Vaccination with Myelin-Reactive T cells: Results of a Clinical Trial in Patients with Multiple Sclerosis. <i>Neurology</i> , 2001;54(7), Supp. 3:A23. <i>Duplicate citation</i>
	C51	ZHANG, J. et al. T cell vaccination in multiple sclerosis. <i>Multiple sclerosis</i> 1(6): 353-56 (1996)
	C52	ZANG, YCQ. et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. <i>Eur J Immunol</i> 60(3) 908-13 (2000)
	C53	ZHANG, J. et al. T-cell vaccination: clinical application in autoimmune diseases. <i>J Mol Med</i> 74(11): 653-62 (1996)
	C54	STINISSEN, P. et al. Vaccination with autoreactive T-cell clones in multiple sclerosis: overview of immunological and clinical data. <i>J Neurosci Res</i> 45(4): 500-11 (1996)
	C55	Zhang, J. et al. T-cell vaccination in multiple sclerosis: Results of a preliminary study. <i>J. Neurol.</i> 2002;243(2):212-8.
	C56	HAFLER, D. et al. T-cell vaccination in multiple sclerosis: a preliminary report. <i>Clin Immunol Immunopathol</i> 62(3): 307-13 (1992)
	C1	ALLEGRETTO, M. et al. T cells responsive to myelin basic protein in patients with multiple sclerosis. <i>Science</i> 247:718-21 (1990)
	C2	BEN-NUN, A. et al. The rapid isolation of clonable antigen-specific T cell lymphocyte lines capable of mediating autoimmune encephalomyelitis. <i>Eur J Immunol</i> 11:195-204 (1981)
	C3	BEN-NUN, A. et al. Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein. <i>Nature</i> 292:60-61 (1981)
	C4	CHOU, YK. et al. Frequency of T cell specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. <i>J Neuroimmunol</i> 38:105-14 (1992)
	C5	CORREALE et al. T cell vaccination in secondary progressive multiple sclerosis. <i>J Neuroimmunol</i> 107:130-39 (2000)
	C6	EUROPEAN STUDY GROUP ON INTERFERON BETA 1-b IN SECONDARY PROGRESSIVE MS. Placebo-controlled multicentre randomized trial of interferon beta 1-b in treatment of secondary progressive multiple sclerosis. <i>Lancet</i> 352:1491-97 (1998)
/M.D./	C7	GENAIN. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. <i>J Clin Invest</i> 96:2966-74 (1995)

Examiner Initials	Cite No#	NON PATENT LITERATURE DOCUMENTS Authors, Title, Journal, Date, Year, Pages, Volume
/M.D./	C8	HAFLER et al. T cell vaccination in multiple sclerosis: a preliminary report. Clinical Immunol and Immunopathology 62:307-13 (1992)
	C9	HONG et al. A common T cell receptor V-D-J sequence in V313.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol 163:3530-38 (1999)
	C10	HONG et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by t cell vaccination. J Immunol 165:6858-64 (2000)
	C11	JACOBS. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-94 (1996)
	C13	KERLERO DE ROSBO et al. Reactivity to myelin antigens in multiple sclerosis: peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 92:2602-08 (1993)
	C14	LIDER. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239:181-83 (1988)
	C15	LINDERT et al. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 122:2089-99 (1999)
	C16	LOHSE AW. et al. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 244:820-22 (1989)
	C17	MARKOVIC-PLESE et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 155:982-92 (1995)
	C18	MEDAER. Depletion of myelin basic protein-reactive T cells by T cell vaccination: a pilot clinical trial in multiple sclerosis. Lancet 346:807-808 (1995)
	C19	NAPARSTEK et al. T lymphocyte lines producing or vaccinating against autoimmune encephalomyelitis (EAE): functional activation induces peanut agglutinin receptors and accumulation in the brain and thymus of line cells. Eur J Immunol 13:418-23 (1983)
	C20	OTA et al. T cell recognition of an immunodominant MBP epitope in multiple sclerosis. Nature 346: 183-87 (1990)
	C21	OFFNER et al. Lymphocyte vaccination against experimental autoimmune encephalomyelitis: evaluation of vaccination protocols. J Neuroimmunol 21:13-22 (1989)
	C22	POSER et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-31 (1983)
	C23	SCHULTENS et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Brain 115:735-48 (1992)
	C24	SELMAJ et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-54 (1991)
	C25	SHARIEF MK. Et al. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472 (1991)
	C26	STINISSEN et al. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol 17:33-75 (1997)
	C27	THE IFNB MULTIPLE SCLEROSIS STUDY GROUP. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurol 43: 655-61 (1993)
	C30	TROTTER et al. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J Neuroimmunology 84:172-78 (1998)
	C31	TROTTER et al. HPRT mutant T cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J Neuroimmunol 75:95-103 (1997)
	C32	TRUYEN et al. Improved correlation of magnetic resonance imaging (MRI) with clinical status in multiple sclerosis (MS) by use of extensive standardized imaging-protocol. J Neurol Sci 96:173-82 (1990)
	C33	TUOHY et al. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 189:1033-42 (1999)
	C34	VANDEVYVER et al. Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: restricted T cell receptor V gene rearrangements and CDR3 sequence. Eur J Immunol 25:958-68 (1995)
	C35	WUCHERPFENNIG et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 152:5581-92 (1994)
/M.D./	C39	ZANG et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurobiology 55: 397-404 (2000)

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No#	Authors, Title, Journal, Date, Year, Pages, Volume
/M.D./	C40	ZANG et al. Aberrant T cell migration toward RANTES and MIP-1alpha in patients with multiple sclerosis overexpression of chemokine receptor CCR5. Brain 123:1874-82 (2000)
↓	C41	ZANG et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol 112:174-80 (2001)
	C43	ZHANG and RAUS. T cell vaccination in autoimmune diseases from laboratory to clinic. Human Immunol 38:87-96 (1993)
	C44	ZHANG et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179:973-84 (1994)
	C45	ZHANG et al. In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. J Immunol 155:5868-77 (1995)
/M.D./	C47	ZHANG, J. et al. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann of Neurology 32(3): 330-38 (1992)

/Marianne DiBrino/

05/14/2009